Hospital Pharmacy Europe

JANUARY 24, 2024

From 22 January 2024, fluoroquinolone antibiotics given systemically – by mouth, injection or inhalation – must only be administered when other recommended antibiotics ‘have failed, will not work due to resistance, or are unsafe to use in an individual patient’, the regulatory agency said.

Adverse Reactions 105

Adverse Reactions Hospitals 105

The Thyroid Pharmacist

DECEMBER 29, 2023

I am hoping to feel more settled in 2024. I am wrapping up some projects in early 2024 and I am carving out more time for myself and my own healing. You can learn more about the results here and be the first to be notified the next time we run it in Fall 2024. Gut Recovery Program (est.

Adverse Reactions 54

Adverse Reactions Immunization Dosage 54

Hospital Pharmacy Europe

MAY 25, 2023

‘Almost a third of adverse reactions to medicines could be prevented with the introduction of genetic testing… This has the potential to transform our safety monitoring activities – enabling us to meet a real need by using high-quality patient data to reduce side effects of medicines.’

Adverse Reactions 98

Adverse Reactions Hospitals 98

European Pharmaceutical Review

NOVEMBER 13, 2023

In these clinical trials, the most common adverse reactions were diarrhoea, thrombocytopaenia, nausea, headache, dizziness, fatigue, asthenia, abdominal pain and cough. GSK shared that a decision on marketing authorisation for momelotinib in the EU is expected by early 2024.

Adverse Reactions 85

Adverse Reactions Pharmaceutical Companies Pharmaceutical Companies 85

Hospital Pharmacy Europe

NOVEMBER 9, 2023

The full pilot involves 25 medicines and will conclude in July 2024. Future developments to the digital system could include functionalities such as automatic update notifications, access to supportive videos or audio content and online adverse-reaction reporting tools, the EMA said.

Adverse Reactions 97

Adverse Reactions Pharmaceutical Companies Pharmaceutical Companies Hospitals 97

European Pharmaceutical Review

FEBRUARY 21, 2023

A marketing authorisation application (MAA) is under review by the European Medicines Agency (EMA) with a regulatory decision expected in early 2024. The safety profile of SYFOVRE is well-demonstrated following ~12,000 injections. SYFOVRE is expected to be available by the beginning of March 2023.

FDA 85

FDA Adverse Reactions 85

Hospital Pharmacy Europe

NOVEMBER 20, 2023

In these clinical trials, the most common adverse reactions were diarrhoea, thrombocytopaenia, nausea, headache, dizziness, fatigue, asthenia, abdominal pain and cough. A decision on EU marketing authorisation is expected for momelotinib by early 2024.

Adverse Reactions 52

Adverse Reactions Hospitals 52